GLP-1RAs for Prediabetes Management
Diabetology & Metabolic Syndrome
Summary
GLP-1RAs combined with lifestyle modifications significantly enhance prediabetes management, reverting prediabetes to normoglycemia and preventing diabetes onset.
Study Design
Interventions
Study Type
Outcomes
Duration and Size
Study Population
Geography
Methodology
A systematic review and meta-analysis of 12 RCTs involving 4,316 patients assessed GLP-1RAs' impact on prediabetes reversion, glycemic control, and safety profiles using standardized statistical tools and quality assessments.
Interventions
Patients received GLP-1RAs like liraglutide and semaglutide, combined with lifestyle modifications, monitored over medium and long-term durations to evaluate glycemic outcomes.
Key Findings
GLP-1RAs significantly improved glycemic parameters and reduced diabetes onset risk with a favorable safety profile, recommending them as adjunct therapy for prediabetes.
Comparison with other Studies
Compared to lifestyle interventions alone, GLP-1RAs show superior efficacy in reversing prediabetes with comparable safety outcomes reported in similar studies.
Journal Reference
Salamah H, Marey A, Abugdida M, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists on prediabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2024;16:129. doi:10.1186/s13098-024-01371-3
Related and Discussions
Key References
Most relevant evidence and guidance related to this research.
Supporting Evidence
Supporting evidence and related resources.
TRIM—Teen Obesity and GLP-1 Receptor Agonists—Insights
The Weight Loss Drug That Can Prevent Diabetes
Eli Lilly's Tirzepatide Shows 94% Reduction in Type 2 Diabetes Risk
The Weight Loss Drug That Can Prevent Diabetes
Lilly's Mounjaro Looks Unstoppable as Trial Wins Pile Up
Your Love Life on Ozempic
30 total sources in this category